Annexon – Talk Bio

Actionable Insights Powered by AI

Annexon Advances Guillain-Barré Syndrome Awareness and Introduces Groundbreaking Targeted Therapy

2 weeks ago talkbio0Tagged Annexon, ANX005, Approved, GBS, Guillain-Barré syndrome, Move GBS Forward™, Phase 3, Phase 3 trial, Tanruprubart, Targeted Therapy, United States Food and Drug Administration

Guillain-Barré Syndrome (GBS) , Annexon , Tanruprubart (ANX005) , Targeted therapy , GBS education campaign , Move GBS Forward™ , Phase 3 trial results , FDA approval

Annexon Shares Soar as ANX005 Meets Primary Endpoint in Phase 3 Trial for Guillain-Barré Syndrome

11 months ago talkbio0Tagged Annexon, ANX005, Disability, Guillain-Barre Syndrome, Phase 3 trial, Prices, Primary Endpoint, Sharing (Social Behavior), surge

Annexon, ANX005, Guillain-Barré Syndrome, Phase 3 Trial, Primary Endpoint, Disability Reduction, Share Price Surge